Latest Breaking News On - Conor richardson - Page 1 : comparemela.com

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesNorth carolinaLini panditeSamer zeidanConor richardsonExchange commissionShattuck labs incChief medical officerBi functional fusion protein targetingPreviously untreated acute myeloid leukemiaHigher risk myelodysplasticShattuck labsAgonist redirected checkpointAnnual reportSafe harborPrivate securities litigation reform act

Shattuck Labs to Present Additional Data from the Phase 1B

Shattuck Labs to Present Additional Data from the Phase 1B
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesNorth carolinaSamer zeidanLini panditeConor richardsonShattuck labs incExchange commissionChief medical officerBi functional fusion protein targetingPreviously untreated acute myeloid leukemiaHigher risk myelodysplasticShattuck labsAgonist redirected checkpointAnnual reportSafe harborPrivate securities litigation reform act

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

02.05.2024 - - Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 .

United statesNorth carolinaMirvetuximab soravtansineConor richardsonClay siegallKate sasserTaylor schreiberExchange commissionOno pharmaceutical co ltdDevelopment rd expensesShattuck labs incAmerican association for cancer researchCancer researchAnnual meetingChief executive officerOno pharma

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired.

San diegoUnited statesSan diego convention centerNorth carolinaConor richardsonGeorge frommTaylor schreiberExchange commissionShattuck labs incCancer cellChief executive officerDysregulated interferon responsivenessChief scientific officerDrug discoveryNew therapiesPresentation number

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesSan diego convention centerNorth carolinaTaylor schreiberConor richardsonGeorge frommShattuck labs incExchange commissionCancer cellChief executive officerDysregulated interferon responsivenessChief scientific officerDrug discoveryNew therapiesPresentation number